• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

氟尿嘧啶、表阿霉素和甲氨蝶呤（FEMTX）联合支持治疗与单纯支持治疗对不可切除胃癌患者的随机比较：S Pyrhönen、T Kuitunen、P Nyandoto 和 M Kouri。

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer: S Pyrhönen, T Kuitunen, P Nyandoto & M Kouri.

机构信息

The Royal Marsden, Downs Road, Sutton, Surrey, SM2 5PT, UK.

出版信息

Br J Cancer. 2023 Feb;128(3):439-440. doi: 10.1038/s41416-023-02146-9. Epub 2023 Feb 16.

DOI:10.1038/s41416-023-02146-9
PMID:36797355
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9938256/
Abstract

We discuss Pyrhönen's paper as a catalyst for defining systemic therapy approaches in gastric cancer and how the field has evolved in the last two decades in sequential, targeted and more recently immune-directed therapies and how it may develop to transform survival in this cancer of high unmet need.

摘要

我们讨论 Pyrhönen 的论文，将其作为定义胃癌系统治疗方法的催化剂，以及该领域在过去二十年中如何逐步发展为序贯、靶向，最近是免疫导向治疗，以及它如何发展以改变这种高未满足需求癌症的生存状况。

相似文献

1
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer: S Pyrhönen, T Kuitunen, P Nyandoto & M Kouri.氟尿嘧啶、表阿霉素和甲氨蝶呤（FEMTX）联合支持治疗与单纯支持治疗对不可切除胃癌患者的随机比较：S Pyrhönen、T Kuitunen、P Nyandoto 和 M Kouri。
Br J Cancer. 2023 Feb;128(3):439-440. doi: 10.1038/s41416-023-02146-9. Epub 2023 Feb 16.
2
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.氟尿嘧啶、表柔比星和甲氨蝶呤（FEMTX）联合支持治疗与单纯支持治疗在不可切除胃癌患者中的随机对照比较。
Br J Cancer. 1995 Mar;71(3):587-91. doi: 10.1038/bjc.1995.114.
3
Phase II study of sequential high-dose methotrexate (MTX) and 5-fluorouracil (F) alternated with epirubicin (E) and cisplatin (P) [FEMTX-P] in advanced gastric cancer.序贯大剂量甲氨蝶呤（MTX）和5-氟尿嘧啶（F）与表柔比星（E）和顺铂（P）交替使用的II期研究[FEMTX-P]在晚期胃癌中的应用
Ann Oncol. 1993 May;4(5):426-8. doi: 10.1093/oxfordjournals.annonc.a058526.
4
Phase II study of sequential high-dose methotrexate and fluorouracil combined with doxorubicin as a neoadjuvant chemotherapy for scirrhous gastric cancer.序贯大剂量甲氨蝶呤和氟尿嘧啶联合阿霉素作为硬癌型胃癌新辅助化疗的II期研究
Gastric Cancer. 2001;4(4):192-7. doi: 10.1007/s10120-001-8009-5.
5
Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma.顺铂、表柔比星、亚叶酸钙和5-氟尿嘧啶（PELF）方案在晚期胃癌中的活性高于5-氟尿嘧啶、多柔比星和甲氨蝶呤（FAMTX）方案。
Ann Oncol. 2003 Aug;14(8):1258-63. doi: 10.1093/annonc/mdg329.
6
Ineffectiveness of sequential high dose methotrexate and 5-fluorouracil combined with epirubicin (FEMTX regimen) as a salvage therapy in advanced colorectal cancers and other gastrointestinal tumors.序贯大剂量甲氨蝶呤和5-氟尿嘧啶联合表柔比星（FEMTX方案）作为晚期结直肠癌和其他胃肠道肿瘤挽救治疗的无效性。
Anticancer Res. 1996 Jul-Aug;16(4A):2063-7.
7
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.氟尿嘧啶+亚叶酸、奥沙利铂和多西紫杉醇与氟尿嘧啶或卡培他滨+顺铂和表柔比星用于局部晚期可切除胃或胃食管交界处腺癌的围手术期化疗（FLOT4）：一项随机、2/3 期试验。
Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11.
8
A phase II trial of sequential MTx and 5-FU alternated with 4-epidoxorubicin and cisplatin in advanced gastric cancer.甲氨蝶呤（MTx）与氟尿嘧啶（5-FU）序贯联合表阿霉素（4-表柔比星）和顺铂用于晚期胃癌的II期试验。
Cancer Invest. 1990;8(5):501-4. doi: 10.3109/07357909009012074.
9
TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).TOPGEAR：一项关于可切除胃癌围手术期ECF化疗与术前放化疗加围手术期ECF化疗对比的随机III期试验（AGITG/TROG/EORTC/NCIC CTG的一项国际多组试验）
BMC Cancer. 2015 Jul 21;15:532. doi: 10.1186/s12885-015-1529-x.
10
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG.辅助性FAMTX或FEMTX与单纯手术治疗对比用于胃癌切除术后的随机III期试验。欧洲癌症研究与治疗组织胃肠癌协作组（EORTC GI Group）和国际癌症协作组（ICCG）的联合分析。
Ann Oncol. 2006 Feb;17(2):262-9. doi: 10.1093/annonc/mdj077. Epub 2005 Nov 17.

本文引用的文献

1
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.KEYNOTE-811 试验：双 PD-1 和 HER2 阻断在 HER2 阳性胃癌中的应用。
Nature. 2021 Dec;600(7890):727-730. doi: 10.1038/s41586-021-04161-3. Epub 2021 Dec 15.
2
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.一线纳武利尤单抗联合化疗与单纯化疗治疗晚期胃癌、胃食管交界癌和食管腺癌（CheckMate 649）：一项随机、开放标签的3期试验。
Lancet. 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5.
3
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies.循环肿瘤 DNA 测序在晚期胃肠道癌中的临床应用：SCRUM-Japan GI-SCREEN 和 GOZILA 研究。
Nat Med. 2020 Dec;26(12):1859-1864. doi: 10.1038/s41591-020-1063-5. Epub 2020 Oct 5.
4
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.曲妥珠单抗-德曲妥珠单抗用于既往治疗的 HER2 阳性胃癌。
N Engl J Med. 2020 Jun 18;382(25):2419-2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29.
5
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.氟尿嘧啶+亚叶酸、奥沙利铂和多西紫杉醇与氟尿嘧啶或卡培他滨+顺铂和表柔比星用于局部晚期可切除胃或胃食管交界处腺癌的围手术期化疗（FLOT4）：一项随机、2/3 期试验。
Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11.
6
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.替氟尿苷/替匹嘧啶对比安慰剂用于既往大量治疗的转移性胃癌患者（TAGS）：一项随机、双盲、安慰剂对照的 3 期临床试验。
Lancet Oncol. 2018 Nov;19(11):1437-1448. doi: 10.1016/S1470-2045(18)30739-3. Epub 2018 Oct 21.
7
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.多西他赛对比积极症状控制治疗难治性胃食管腺癌（COUGAR-02）：一项开放标签、3 期随机对照试验。
Lancet Oncol. 2014 Jan;15(1):78-86. doi: 10.1016/S1470-2045(13)70549-7. Epub 2013 Dec 10.
8
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.曲妥珠单抗联合化疗与单纯化疗治疗 HER2 阳性晚期胃或胃食管交界腺癌（ToGA）：一项开放标签、随机对照的 3 期临床试验。
Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19.
9
Capecitabine and oxaliplatin for advanced esophagogastric cancer.卡培他滨与奥沙利铂用于晚期食管胃癌
N Engl J Med. 2008 Jan 3;358(1):36-46. doi: 10.1056/NEJMoa073149.
10
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.可切除的胃食管癌围手术期化疗与单纯手术治疗的比较
N Engl J Med. 2006 Jul 6;355(1):11-20. doi: 10.1056/NEJMoa055531.